Cost-effectiveness analysis of empagliflozin in the treatment of patients with type 2 diabetes and established cardiovascular disease in Italy, based on the results of the EMPA-REG OUTCOME study. Farmeconomia. Health economics and therapeutic pathways, [S. l.], v. 18, n. 1, 2017. DOI: 10.7175/fe.v18i1.1332. Disponível em: https://journals.seedstm.com/index.php/FE/article/view/1332. Acesso em: 29 oct. 2025.